MNG461
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.533
- PROTEIN_SECRETION+0.494
- NOTCH_SIGNALING+0.490
- WNT_BETA_CATENIN_SIGNALING+0.473
- MITOTIC_SPINDLE+0.448
- HEDGEHOG_SIGNALING+0.446
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.443
- UV_RESPONSE_DN+0.427
- ANGIOGENESIS+0.414
- DNA_REPAIR+0.357
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.373
- SPERMATOGENESIS-0.286
- KRAS_SIGNALING_DN-0.243
- ESTROGEN_RESPONSE_LATE-0.122
- CHOLESTEROL_HOMEOSTASIS-0.093
- XENOBIOTIC_METABOLISM-0.044
- BILE_ACID_METABOLISM-0.037
- MTORC1_SIGNALING-0.025
- OXIDATIVE_PHOSPHORYLATION-0.013
- MYC_TARGETS_V2-0.011
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934726 | — | — | 0.836 |
| 2 | TCGA-XF-A9T4-01A-11R-A39I-07 | — | — | 0.834 |
| 3 | 01169BCB-82ED-4492-9FD0-630CCEA70023 | — | — | 0.822 |
| 4 | TCGA-50-5933-01A-11R-1755-07 | — | cohortA1 | 0.821 |
| 5 | F8F6611A-A71A-4847-92B2-15723B9ED0B8 | — | — | 0.820 |
| 6 | BF513557-1518-4843-9F62-837B557D4CAB | — | — | 0.817 |
| 7 | TCGA-49-6745-01A-11R-1858-07 | — | cohortA1 | 0.816 |
| 8 | TCGA-FD-A62S-01A-11R-A30C-07 | — | — | 0.813 |
| 9 | 1A9B5D3A-CEB0-4225-9C3D-CBE98A007A3A | — | — | 0.808 |
| 10 | 4A97D63A-CB64-4D34-8348-D7E912EC5A95 | — | — | 0.808 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.533 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.494 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.490 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.473 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.448 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.446 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.443 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.427 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.414 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.357 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.353 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.319 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.305 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.297 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.283 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.276 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.262 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.253 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.237 | Inavolisib | — uncovered |
| COMPLEMENT | 0.236 | Inavolisib | — uncovered |